News & Articles
Written by the physicians who build eNavvi. What is shifting in prescribing, access and cost — and what we ship in response.
107 articles
Perimenopause Prescribing in 2026: Why Compounding Is the Missing Piece
Estrogen-based hormone replacement therapy prescribing has more than doubled since 2018. The most dramatic increase is in the perimenopause population: as of February 2026, 1 in 20 women aged 45–54…
Read more
Compounded Finasteride, Minoxidil, and Beyond: A Prescriber’s Guide to Hair Loss Compounding
The hair loss treatment market is projected to reach $7.28 billion by 2032, and compounding pharmacies are an increasingly important part of that landscape. For prescribers, the shift is already…
Read more
Women’s HRT in 2026: The Estrogen Shortage, the Access Gap, and Where Compounding Fits
Hormone replacement therapy prescriptions for women aged 50–65 have increased 86% since 2021. The FDA removed boxed warnings on HRT products last year, citing evolving evidence on safety and newer…
Read more
AAD 2026: The Compounding Conversations Every Dermatology Prescriber Should Be Having
As thousands of dermatologists, residents, and prescribers gather in Denver for the American Academy of Dermatology’s 2026 Annual Meeting, the scientific sessions will cover the usual spectrum:…
Read moreverified prescribers already on eNavvi — every one identity-proofed and license-checked.
